Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.89.

Several research firms recently issued reports on ATEC. Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a report on Monday, June 16th. Wall Street Zen raised Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Piper Sandler reissued an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Alphatec in a research note on Monday, April 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd.

Alphatec Stock Up 0.5%

NASDAQ:ATEC opened at $10.94 on Friday. Alphatec has a 52 week low of $4.88 and a 52 week high of $13.14. The company has a market capitalization of $1.60 billion, a P/E ratio of -9.51 and a beta of 1.10. The stock's fifty day moving average is $11.80 and its two-hundred day moving average is $10.85.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The firm had revenue of $169.18 million during the quarter, compared to analysts' expectations of $167.57 million. Alphatec had a negative net margin of 25.77% and a negative return on equity of 1,657.19%. Alphatec's quarterly revenue was up 22.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.34) EPS. Sell-side analysts anticipate that Alphatec will post -1.08 earnings per share for the current fiscal year.

Insider Transactions at Alphatec

In other news, Director Karen K. Mcginnis sold 3,963 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $12.11, for a total transaction of $47,991.93. Following the completion of the transaction, the director now directly owns 68,709 shares of the company's stock, valued at approximately $832,065.99. This represents a 5.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Craig E. Hunsaker sold 186,122 shares of the company's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $12.34, for a total value of $2,296,745.48. Following the transaction, the executive vice president now directly owns 1,463,896 shares of the company's stock, valued at approximately $18,064,476.64. This represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 294,065 shares of company stock valued at $3,633,172. 20.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Nuveen LLC acquired a new stake in shares of Alphatec in the 1st quarter valued at about $135,874,000. Vanguard Group Inc. boosted its position in shares of Alphatec by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company's stock valued at $60,990,000 after purchasing an additional 45,792 shares during the period. American Century Companies Inc. boosted its position in shares of Alphatec by 16.9% in the 1st quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company's stock valued at $59,117,000 after purchasing an additional 840,974 shares during the period. Royal Bank of Canada boosted its position in shares of Alphatec by 10.8% in the 1st quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company's stock valued at $35,773,000 after purchasing an additional 342,656 shares during the period. Finally, Nuveen Asset Management LLC boosted its position in shares of Alphatec by 78.4% in the 4th quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock valued at $23,730,000 after purchasing an additional 1,136,330 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.